Zoetis
Parsippany, New Jersey, United States · Animal Feed, Biotechnology, Health Care
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide – from livestock farmers to veterinarians and pet owners. The company’s leading portfo
Key facts
- Headquarters
- Parsippany, New Jersey, United States
- Employees
- 15,000
- Industries
- Animal Feed, Biotechnology, Health Care
- Status
- Public (ZTS)
- Website
- www.zoetis.com
- Company page
Recent activity at Zoetis
- : SEC 8-K (7.01): On October 8, 2026, Zoetis Inc. declared a dividend of $0.53 per share for the fourth quarter of 2026. This dividend is set to be paid on December 1, 2026, to all shareholders who are on record by the close of business on October 30, 2026. This strategic decision reflects the company's ongoing commitment to return value to its shareholders and signals confidence in its future cash flow. Additionally, this filing communicates key financial information relevant to investors regarding the company's dividend policy and timelines.
- : SEC 8-K (5.02):
- : Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer
- : SEC 8-K (5.02): On August 6, 2026, Zoetis Inc. appointed James Saccaro as the Executive Vice President, Chief Financial Officer, and Chief Operating Officer, effective August 17, 2026. Mr. Saccaro, who has over eight years of experience in executive financial roles at significant companies, will oversee Zoetis’ global finance function and drive operational performance. His offer includes an annual salary of $1,000,000, a target bonus, long-term incentives potentially totaling $5,000,000, and a one-time restricted stock unit award valued at $6,250,000, which will vest over three years. Additionally, he will receive a one-time cash award of $1,250,000, contingent on certain termination conditions.
- : SEC 8-K (2.02): On August 6, 2026, Zoetis Inc. reported its financial results for the second quarter of 2026 and provided guidance for the full year 2026. The press release, which is attached as Exhibit 99.1, provides a comprehensive overview of the company's financial condition, including revenue figures, net income, and projected earnings for the upcoming year. The update is significant as it reflects the company's ongoing strategy and market position in the veterinary pharmaceuticals industry. This timely disclosure is intended to keep investors informed about the firm's performance and future expectations.
- : Zoetis to acquire Neogen Corporation amid competition concerns
- : Zoetis to acquire VitalRADS for diagnostics boost
- : SEC 8-K (5.02): Effective May 20, 2026, Ms. Louise M. Parent retired from the Board of Directors of Zoetis Inc. in accordance with the company’s director retirement policy, prior to the 2026 Annual Meeting of Shareholders. Alongside her retirement, the Company held the Annual Meeting on the same date, where shareholders voted on five proposals, including the election of twelve directors and advisory votes on executive compensation. A total of 379,034,516 shares were present, constituting a quorum, with significant voting results for each nominee provided. The event represents a strategic transition in the board that could influence future governance and company direction.
- : SEC 8-K (7.01): On May 20, 2026, Zoetis Inc. declared a dividend of $0.53 per share for the third quarter of 2026. This dividend will be paid on September 1, 2026, to all holders of record of the Company’s common stock as of the close of business on July 20, 2026. This announcement is significant for shareholders as it indicates ongoing financial stability and a commitment to returning value to shareholders despite potential challenges in the market. The declaration date is within three days of this filing, complying with regulations under the Securities Exchange Act.
- : SEC 8-K (7.01): On May 20, 2026, Zoetis Inc. declared a dividend of $0.53 per share for the third quarter of 2026. This dividend is scheduled to be paid on September 1, 2026, to all holders of record of the Company’s common stock as of the close of business on July 20, 2026. This announcement reflects the company's ongoing commitment to providing returns to its shareholders and positions them for future financial stability. The declaration of this dividend on May 20, 2026, signals the company's operational success and cash flow management amid its market activities.
Leadership
- Jay Saccaro, Chief Operating Officer
- Kristin Peck, Chief Executive Officer
- Williams, VP, Chief Data and Analytics Officer
- Jamie Brannan, Chief Commercial Officer
- Ester Banque, Vice President
Verified email and direct lines for Zoetis’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Zoetis files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Zoetis in the news
- Zoetis' Q3 2026 Earnings: What to Expect - Yahoo Finance (Oct 27, 2026)
- Syngene Q2 Profit Falls 52% To ₹32 Crore As Lower Zoetis Revenue, Forex Losses Hit Margins - Business Today (Oct 28, 2026)
- Zoetis (ZTS) Ascends While Market Falls: Some Facts to Note - Yahoo Finance (Oct 29, 2026)
- Zoetis (ZTS) Stock Looks Reasonable Despite Its 61% Five Year Slide - Simply Wall St (Oct 28, 2026)
- Why Is Zoetis (NYSE:ZTS) Drawing Fresh Attention as Animal Health Awaits Its Report? - Kalkine Media (Oct 29, 2026)
Companies similar to Zoetis
- Greencross · Animal Feed, Biotechnology, Health Care, Medical, Pet, Veterinary
- Elanco Animal Health · Animal Feed, Biotechnology, Health Care, Pet, Veterinary
- EBOS Group · Animal Feed, Biotechnology, Health Care, Pet, Veterinary
- National Veterinary Associates · Animal Feed, Health Care, Pet, Veterinary
- IDEXX Laboratories · Animal Feed, Biotechnology, Health Care, Pet
About Zoetis: questions and answers
What does Zoetis do?
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide – from livestock farmers to veterinarians and pet owners. The company’s leading portfo
Where is Zoetis headquartered?
Zoetis is headquartered in Parsippany, New Jersey, United States.
How many employees does Zoetis have?
Zoetis has about 15,000 employees.
Who leads Zoetis?
Kristin Peck is a Chief Executive Officer at Zoetis.
What is the latest news on Zoetis?
On Oct 08, 2026, SEC 8-K (7.01): On October 8, 2026, Zoetis Inc. declared a dividend of $0.53 per share for the fourth quarter of 2026. This dividend is set to be paid on December 1, 2026, to all shareholders who are on record by the close of business on October 30, 2026. This strategic decision reflects the company
Is Zoetis a public company?
Yes. Zoetis is publicly traded under the ticker ZTS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy